We evaluated the incidence and outcome of lung involvement in 35 patients with autoimmune pancreatitis (AIP). Our results indicate that lung involvement is commonly observed in AIP (40%). In addition, corticosteroid treatment improved the lung lesions and appeared to reduce the probability of relapse compared with pancreatic lesions (0% vs 36%). This is the first report to assess the long-term outcome of lung involvement in AIP (52 ± 33 months).Key words: autoimmune pancreatitis, immunoglobulin G4, immunoglobulin G4-related disease, immunoglobulin G4-related lung disease, type 1 autoimmune pancreatitis.Abbreviations: AIP, autoimmune pancreatitis; CT, computed tomography; IgG4-RD, immunoglobulin G4-related disease; L-AIP, autoimmune pancreatitis with lung involvement; NL-AIP, autoimmune pancreatitis without lung involvement.Immunoglobulin G4-related disease (IgG4-RD) is a recently described systemic fibroinflammatory condition associated with an elevated serum IgG4 level and abundant IgG4-positive plasma cell infiltration involving multiple organs.1,2 Type 1 autoimmune pancreatitis (AIP) is the prototypical form of systemic IgG4-RD, and various clinical findings have been documented for this disease. Early intervention using corticosteroids has been shown to improve IgG4-related organ dysfunction, although relapse of the disease is common. In addition, various types of lung involvement in IgG4-RD, including interstitial pneumonia, inflammatory pseudotumours and lymphadenopathy, have been described. [3][4][5][6][7] In contrast, the clinical characteristics of lung involvement in IgG4-RD, in particular the response to treatment and prognosis, remain unclear. In this study, we retrospectively evaluated the incidence and outcomes of lung involvement in 35 patients with AIP.Between December 1996 and March 2011, a total of 35 patients with type 1 AIP diagnosed at our university hospital according to the consensus diagnostic criteria 8,9 were consecutively enrolled in this study (24 males and 11 females, average age: 67 ± 9), with a median follow-up time of 52 ± 33 months (range: 5-160 months). All patients were examined using chest and abdominal computed tomography (CT) at the time of diagnosis and relapse, and underwent chest X-ray examinations at least every 6 months, regardless of the presence or absence of respiratory symptoms. In addition, all patients regularly received medical examinations by a physician using abdominal ultrasound and assessments of biochemical parameters, including serum IgG4 levels. Lung involvement in AIP was diagnosed based on findings of chest CT abnormalities accompanied by compatible X-ray findings associated with IgG4-related lung disease, with or without a favourable response to corticosteroid therapy. Definitive diagnosis for a relapse of AIP and lung involvement was according to the CT findings since re-elevation of the serological levels alone without any abnormal CT findings is not considered to indicate a relapse. [10][11][12][13] We retrospectively reviewed the following data: (i)...